Cardiovascular disease (CVD) remains the leading cause of global morbidity and mortality. Accurate risk stratification is essential for guiding preventive strategies, optimizing treatment decisions, and allocating healthcare resources effectively. In 2021, the European Society of Cardiology (ESC) introduced Systematic Coronary Risk Evaluation 2 (SCORE2)—a major update to its widely used cardiovascular risk assessment model—to address evolving epidemiological patterns, improve predictive accuracy across diverse populations, and incorporate modern risk factors.

What Is SCORE2?

SCORE2 is a set of sex-specific statistical models designed to estimate the 10-year risk of fatal and non-fatal atherosclerotic cardiovascular disease (ASCVD)—including myocardial infarction, sudden cardiac death, stroke, and other hard ASCVD events—in adults aged 40–79 years who do not have established CVD or diabetes mellitus. It replaces the original SCORE model and its 2012 revision (SCORE2-OP for older adults), reflecting updated data and methodological advances.

Key Features and Innovations

1. Expanded Age Range and Population

• Covers individuals aged 40–79 years.
• Specifically designed for those without prior CVD or diabetes—populations in whom primary prevention decisions are most critical.

2. Updated Data Source

SCORE2 is based on pooled individual-level data from 13 prospective cohort studies across 15 European countries, with over 300,000 participants and up to 17 years of follow-up—making it more representative than ever before.

3. Risk Prediction Models

Two models are provided:

• SCORE2-O (for low–moderate-risk regions): Estimated for countries with a baseline 10-year fatal CVD risk <1% in 40-year-olds.
• SCORE2-H (for high-risk regions): Estimated for countries with ≥1% baseline fatal CVD risk.

Models are stratified by:

• Sex (male/female)
• Age (continuous variable, most accurate when entered as linear + restricted cubic spline terms)
• Smoking status (current vs. non-current smoker)
• Total cholesterol (mg/dL or mmol/L)
• Systolic blood pressure (mmHg)

Notably, SCORE2 does not require HDL cholesterol or body mass index (BMI), simplifying clinical use while retaining robust predictive performance.

4. Outcome Definition

Predicts the combined endpoint of:

• Fatal coronary heart disease (CHD)
• Non-fatal myocardial infarction
• Fatal stroke
• Non-fatal stroke

ThisASCVD-focused approach aligns with contemporary definitions used in international guidelines (e.g., ESC/EASD, AHA/ACC).

How SCORE2 Compares to Previous Models

Clinical Utility

SCORE2 supports personalized risk communication and shared decision-making:

• A 10-year risk ≥5% is generally considered high enough to warrant lifestyle counseling and consideration of pharmacotherapy (e.g., antihypertensives or statins) in intermediate-risk individuals.
• For many patients, a SCORE2 score <5% may support less aggressive interventions, reducing over-treatment.

Importantly, clinicians are encouraged to adjust risk estimates based on individual patient factors not captured by the model—such as family history of premature CVD, chronic kidney disease, metabolic syndrome, or persistent psychosocial stressors.

Limitations

• Excludes patients with diabetes: A separate model (SCORE2-DIAB) was developed for this subgroup.
• Underestimates risk in some high-risk subgroups, including South Asians and individuals with long-standing hypertension or elevated Lp(a).
• Primarily validated in European populations; adaptation may be needed for non-European regions.
• Does not incorporate biomarkers like hs-CRP, apoB, or coronary artery calcium (CAC) scoring—though SCORE2 can be combined with CAC for refined risk stratification.

Implementation Tips

1. Use digital tools: The ESC Risk Calculator app and online platforms (e.g., ESC CardioSmart) automate calculations.
2. Consider region-specific models: Select SCORE2-O or SCORE2-H based on your country’s baseline CVD mortality (e.g., use SCORE2-H in Eastern Europe, SCORE2-O in Scandinavia).
3. Integrate clinical judgment: Risk calculators inform—not replace—clinical reasoning.

Conclusion

SCORE2 represents a significant advancement in cardiovascular risk prediction, offering a validated, practical tool for identifying individuals who stand to benefit most from preventive strategies. By accurately estimating 10-year ASCVD risk in primary prevention populations—and supporting individualized, evidence-based care—it empowers clinicians to shift from reactive to proactive cardiology.

As new data emerge (e.g., on novel biomarkers and genetic risk scores), future iterations will likely further refine these models—making SCORE2 an important step toward precision preventive medicine.

References

1. Perk J, et al. European Heart Journal (2021). 42(4):357–369. [SCORE2 development paper]
2. ESC Guidelines on cardiovascular disease prevention in clinical practice (2021)
3. Esembajev A, et al. European Heart Journal – Cardiovascular Pharmacotherapy (2022). Validation and calibration of SCORE2.
4. ESC Risk Calculator: https://www.escardio.org/Professional/Reference/Guidelines/Pages/Esc-Risk-Calculator.aspx

Disclaimer: This article is for educational purposes only. Clinical decisions should be based on individual patient assessment, current guidelines, and shared decision-making.